Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi Expands MS Portfolio With BTK Inhibitor From Principia

Executive Summary

The French pharma adds the Phase I candidate to its Lemtrada follow-on for multiple sclerosis development, while Principia will use $40m in upfront cash to advance its orphan disease strategy.


Related Content

Deal Watch: Genentech Expands Upon Arvinas PROTAC Collaboration
Deal Watch: Boehringer’s Hectic Stretch Adds Up To Five Deals
MS Franchise A Surprising Concern For Sanofi In Q3; Dupixent Out-Performs
AstraZeneca's Calquence Steps Into Blood Cancer Ring With Mighty Imbruvica
Sanofi R&D Chief Zerhouni: How I'm Doing More With Less
Is Neuroscience Back In Vogue? Sanofi Preps For R&D Dominance
Principia taps Series A tranche to arm warheads for covalent drug IND


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts